Inulin,SCFA Production and Metabolic Response

Maastricht University Medical Centre (MUMC)

Status: Completed

Conditions: Type 2 Diabetes Mellitus; Obesity

Treatments: Dietary Supplement: 13C inulin; Other: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT02009670

Inulin and SCFA production

Details and patient eligibility

About

In this placebo controlled, double-blind, randomized crossover study the investigators will investigate in overweight/obese healthy male volunteers whether inulin administration will increase intestinal SCFA production, thereby investigating whether this will lead to acute metabolic effects.

Full description

Gut microbiota is being increasingly recognized as an important factor in fat distribution, insulin sensitivity and glucose and lipid metabolism. Accordingly, the intestinal microbiota could play an important role in the development of obesity and type 2 diabetes mellitus. The role of gut-derived short-chain fatty acids (SCFA), the formation of which is enhanced by microbial fermentation of fibre, is still controversial. At the present time, our understanding of the effects of SCFA on human metabolism (in gut or systemically) is still limited. The investigators hypothesize that the ingested prebiotic inulin is fermented into SCFA and these SCFA have metabolic effects.

Enrollment: 15 patients

Sex: Male

Ages: 20 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Overweight, obese men

Exclusion criteria

• athletes
• diabetes mellitus

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

15 participants in 2 patient groups, including a placebo group

13C inulin

Experimental group

Description:

13C inulin combined with an inulin load are administered orally

Treatment:

Dietary Supplement: 13C inulin

Placebo

Placebo Comparator group

Description:

A placebo is administered orally

Treatment:

Other: Placebo